REG - Nuformix PLC - £1.0 million Placing

NuformixAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260311:nRSK1290Wa&default-theme=true

RNS Number : 1290W  Nuformix PLC  11 March 2026

THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR
PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN
PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH
AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH
PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR"). IN ADDITION, MARKET
SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE
MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE
PERSONS WHO RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN
POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE
PUBLIC DOMAIN.

 

11 March 2026

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

£1.0 million Placing

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces a
placing (the "Placing") to raise gross proceeds of £1.0 million through the
issue of 500,000,000 new ordinary shares ("New Ordinary Shares") in the
capital of the Company at a price of 0.20 pence per share (the "Issue Price").

 

The net proceeds of the Placing will be used by the Company to drive forward
its NXP002 programme, an inhaled treatment for idiopathic pulmonary fibrosis
("IPF") and progressive pulmonary fibrosis ("PPF") and for general corporate
purposes.  In particular, the net proceeds will be used to fund a focused
programme of additional pre-clinical studies to reinforce areas identified
during ongoing out-licensing discussions and due diligence with both large
pharmaceutical and speciality pharma partners, and to further advance the
NXP002 programme.  Whilst completion of the focused studies will represent
important value inflection points for the NXP002 programme it is not expected
that all the studies will need to conclude for an out-licensing or
collaborative development transaction to complete.

 

CMC Markets UK Plc, trading as CMC CapX ("CMC Markets"), acted as the
Company's sole placing agent in respect of the Placing.

 

Admission and Total Voting Rights

 

The Placing has been conducted utilising the Directors existing authorities to
allot shares.  The New Ordinary Shares will rank pari passu in all respects
with the existing ordinary shares.  The Placing is conditional, inter alia,
on there being no breach of the obligations under the Placing Agreement
entered into between CMC Markets and the Company prior to Admission, and
admission of the New Ordinary Shares to trading on the Main Market of the
London Stock Exchange ("Admission") becoming effective.

 

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on the Main Market of the London Stock
Exchange and the Equity Shares (Transition) category of the FCA Official
List.  It is expected that Admission will become effective and that dealings
in the New Ordinary Shares on the Main Market of the London Stock Exchange
will commence on or around 17 March 2026.

 

Following Admission of the New Ordinary Shares, the total number of ordinary
shares in issue will be 2,609,749,903, each with one voting right.  The
Company does not hold any rights in treasury.  The total voting rights figure
is therefore 2,609,749,903 and can be used by shareholders as the denominator
for the calculations by which they will determine whether they are required to
notify their interest in, or a change of their interest in, the Company under
the Disclosure Guidance and Transparency Rules of the Financial Conduct
Authority.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6632

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEAKKBKBBKBBND



            Copyright 2019 Regulatory News Service, all rights reserved